IR@PKUHSC  > 北京大学第三临床医学院  > 肿瘤放疗科
学科主题临床医学
The investigation of I-125 seed implantation as a salvage modality for unresectable pancreatic carcinoma
Wang, Hao1; Wang, Junjie1; Jiang, Yuliang1; Li, Jinna1; Tian, Suqing1; Ran, Weiqiang2; Xiu, Dianrong3; Gao, Yang1
关键词I-125 seed Intraoperative implantation Ultrasound-guided Unresectable Pancreatic carcinoma
刊名JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
2013-12-27
DOI10.1186/1756-9966-32-106
32
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Oncology
研究领域[WOS]Oncology
关键词[WOS]EXTERNAL-BEAM RADIATION ; PROTRACTED 5-FLUOROURACIL INFUSION ; PHASE-II ; INTRAOPERATIVE RADIOTHERAPY ; CONCURRENT RADIOTHERAPY ; SURGICAL RESECTION ; BYPASS PROCEDURES ; I125 IMPLANT ; CANCER ; ADENOCARCINOMA
英文摘要

Background: To assess the efficacy of intraoperative ultrasound-guided implantation of I-125 seeds for the treatment of unresectable pancreatic carcinoma, and analyze the associated prognostic factors.

Methods: Twenty-eight patients with pancreatic carcinoma who underwent laparotomy and were considered to have unresectable tumors were included in this study. Nine patients were pathologically diagnosed with Stage II disease, and nineteen patients with Stage III disease. Twenty-eight patients received intraoperative ultrasound-guided I-125 seed implantation and received a D-90 (at least 90% of the tumor volume received the reference dose) ranging from 60 to 163 Gy, with a median of 120 Gy. Seven patients received an additional 35-50 Gy external beam radiotherapy after seed implantation, and ten patients received two to ten cycles of chemotherapy. Overall survival of the patients was calculated and prognostic factors were evaluated.

Results: Of the patients, 94.1% (16/17) achieved good to medium pain relief. The tumor response rate was 78.6% (22/28), and local control was achieved in 85.7% (24/28) of patients. The 1-, 2- and 3-year survival rates were 30%, 11% and 4%, and the median survival was 10.1 months (95% CI: 9.0-10.9). Analysis using the Cox proportional hazards model suggested that patients younger than 60 years and patients who received a D-90 higher than 110 Gy may survive for a longer period.

Conclusions: I seed implantation provides a safe and effective method to relieve pain, control local tumor growth and, to some extent, prolong the survival of patients with stage II and III pancreatic disease, without additional complications. Age and accumulated dose may be factors predictive of a favorable outcome for patients with unresectable pancreatic carcinoma treated with I-125 seeds. These findings need to be validated by conducting further studies with larger cohorts.

语种英语
WOS记录号WOS:000331739400002
项目编号81071834
资助机构National Science Foundation of China
引用统计
被引频次:22[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/59215
专题北京大学第三临床医学院_肿瘤放疗科
北京大学第二临床医学院_肝病科
北京大学第三临床医学院_肿瘤治疗中心
作者单位1.Peking Univ, Hosp 3, Dept Surg, Beijing 100083, Peoples R China
2.Peking Univ, Hosp 3, Dept Radiat Oncol, Beijing 100083, Peoples R China
3.Peking Univ, Hosp 3, Dept Ultrasound, Beijing 100083, Peoples R China
推荐引用方式
GB/T 7714
Wang, Hao,Wang, Junjie,Jiang, Yuliang,et al. The investigation of I-125 seed implantation as a salvage modality for unresectable pancreatic carcinoma[J]. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH,2013,32.
APA Wang, Hao.,Wang, Junjie.,Jiang, Yuliang.,Li, Jinna.,Tian, Suqing.,...&Gao, Yang.(2013).The investigation of I-125 seed implantation as a salvage modality for unresectable pancreatic carcinoma.JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH,32.
MLA Wang, Hao,et al."The investigation of I-125 seed implantation as a salvage modality for unresectable pancreatic carcinoma".JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH 32(2013).
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Wang, Hao]的文章
[Wang, Junjie]的文章
[Jiang, Yuliang]的文章
百度学术
百度学术中相似的文章
[Wang, Hao]的文章
[Wang, Junjie]的文章
[Jiang, Yuliang]的文章
必应学术
必应学术中相似的文章
[Wang, Hao]的文章
[Wang, Junjie]的文章
[Jiang, Yuliang]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。